Association of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccination and Reductions in Post COVID Conditions Following Severe Acute Respiratory Syndrome Coronavirus 2 Infection in a US Prospective Cohort of Essential Workers.
Article in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
34 authors.
Josephine MakNational Center for Immunization and Respiratory Disease, Centers for Disease Control and Prevention, Atlanta, Georgia.ORCID 0000-0001-9557-2690
Sana KhanDepartment of Epidemiology and Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona.ORCID 0000-0003-0699-2103
Amadea BrittonNational Center for Immunization and Respiratory Disease, Centers for Disease Control and Prevention, Atlanta, Georgia.ORCID 0000-0003-2684-8846
Spencer RoseDepartment of Pediatrics, Baylor Scott and White Health, Temple, Texas.
Lisa GwynnDepartment of Pediatrics, Leonard M. Miller School of Medicine, University of Miami, Miami, Florida.ORCID 0000-0003-2857-376X
Katherine D EllingsonDepartment of Epidemiology and Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona.
Jennifer MeeceMarshfield Clinic Research Institute, Marshfield, Wisconsin.
Leora R FeldsteinNational Center for Immunization and Respiratory Disease, Centers for Disease Control and Prevention, Atlanta, Georgia.ORCID 0000-0002-4430-6760
Harmony TynerDepartment of Medicine, Division of Infectious Disease, St Luke's Regional Health Care System, Duluth, Minnesota.ORCID 0000-0002-4130-0793
Laura J EdwardsAbt Associates Inc, Rockville, Maryland.
Matthew S ThieseRocky Mountain Center for Occupational and Environmental Health, Division of Occupational and Environmental Health, University of Utah Health, Salt Lake City, Utah.ORCID 0000-0003-4505-2907
Allison NalewayKaiser Permanente Center for Health Research, Portland, Oregon.ORCID 0000-0001-5747-4643
Manjusha GaglaniDepartment of Pediatrics, Baylor Scott and White Health, Temple, Texas.ORCID 0000-0002-3952-9230
Natasha SolleDepartment of Medicine, Leonard M. Miller School of Medicine, University of Miami, Miami, Florida.
Jefferey L BurgessDepartment of Community, Environment and Policy, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona.ORCID 0000-0003-2362-9509
Julie Mayo LamberteNational Center for Immunization and Respiratory Disease, Centers for Disease Control and Prevention, Atlanta, Georgia.ORCID 0000-0002-8134-9081
Taryn Hunt-SmithRocky Mountain Center for Occupational and Environmental Health, Division of Occupational and Environmental Health, University of Utah Health, Salt Lake City, Utah.ORCID 0000-0002-9421-2105
Alberto Caban-MartinezDepartment of Public Health Sciences, Leonard M. Miller School of Medicine, University of Miami, Miami, Florida.ORCID 0000-0002-5960-1308
Cynthia PorterDepartment of Epidemiology and Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona.ORCID 0000-0001-9232-0279
Ryan WiegandNational Center for Immunization and Respiratory Disease, Centers for Disease Control and Prevention, Atlanta, Georgia.
Kurt T HegmannRocky Mountain Center for Occupational and Environmental Health, Division of Occupational and Environmental Health, University of Utah Health, Salt Lake City, Utah.
James HollisterDepartment of Community, Environment and Policy, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona.ORCID 0000-0002-4328-1071
Ashley FowlkesNational Center for Immunization and Respiratory Disease, Centers for Disease Control and Prevention, Atlanta, Georgia.ORCID 0000-0002-0620-6451
Andrew L PhilipsRocky Mountain Center for Occupational and Environmental Health, Division of Occupational and Environmental Health, University of Utah Health, Salt Lake City, Utah.ORCID 0000-0003-2320-3567
Patrick RiversDepartment of Family and Community Medicine, College of Medicine-Tucson, University of Arizona, Tucson, Arizona.ORCID 0000-0001-5195-518X
Sarang K YoonRocky Mountain Center for Occupational and Environmental Health, Division of Occupational and Environmental Health, University of Utah Health, Salt Lake City, Utah.ORCID 0000-0002-8500-2886
Sharon SaydahNational Center for Immunization and Respiratory Disease, Centers for Disease Control and Prevention, Atlanta, Georgia.ORCID 0000-0002-6350-5300
Karen LutrickDepartment of Family and Community Medicine, College of Medicine-Tucson, University of Arizona, Tucson, Arizona.ORCID 0000-0003-3480-849X
Funding
CTSA UM1 Program at University of UtahUM1TR004409 · NCATS · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI RACHEL HESS, Jennifer Juhl Majersik · 2023 to 2026
backgroundData are limited on whether vaccination reduces post COVID conditions (PCCs) risk after less severe nonhospitalized coronavirus disease 2019 (COVID-19). This study assessed whether COVID-19 vaccination protected against PCCs in persons with mild initial infections during Delta and Omicron variant predominance.
methodsThis study utilized a case-control design, nested within the HEROES-RECOVER cohort. Participants aged ≥18 years with test-confirmed severe acute respiratory syndrome coronavirus disease 2 (SARS-CoV-2) between 28 June 2021 and 14 September 2022 were surveyed for PCCs, defined by symptoms lasting >4 weeks after initial infection. Cases self-reported PCCs and controls self-reported no PCCs. The exposure was messenger RNA (mRNA) COVID-19 vaccination (2 or 3 monovalent doses). Odds of PCCs among vaccinated and unvaccinated persons were compared with logistic regression.
resultsOf 936 participants, 23.6% reported PCCs and 83.2% were vaccinated. Participants who received 3 vaccine doses had lower odds of PCC-related gastrointestinal, neurological, and other symptoms compared to unvaccinated participants (adjusted odds ratio [95% confidence interval]: 0.37 [.16-.85], 0.56 [.32-.97], and 0.48 [.25-.91], respectively).
conclusionsCOVID-19 vaccination protected against development of PCCs among persons with mild infection during both Delta and Omicron variant predominance, supporting vaccination as an important PCCs prevention tool.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Association of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccination and Reductions in Post COVID Conditions Following Severe Acute Respiratory Syndrome Coronavirus 2 Infection in a US Prospective Cohort of Essential Workers. · full record | OpenQuestion